Vaxcyte, Inc. Files 8-K on Shareholder Vote Matters
Ticker: PCVX · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1649094
| Field | Detail |
|---|---|
| Company | Vaxcyte, Inc. (PCVX) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing
Related Tickers: PCVX
TL;DR
Vaxcyte filed an 8-K for shareholder vote matters, nothing major to see here.
AI Summary
Vaxcyte, Inc. filed an 8-K on June 17, 2025, reporting on matters submitted to a vote of security holders as of June 12, 2025. The filing details routine corporate governance information and does not appear to disclose any new material events or financial transactions.
Why It Matters
This filing indicates Vaxcyte is adhering to corporate governance requirements by reporting on shareholder votes. It provides transparency to investors regarding company decision-making processes.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on matters submitted to a vote of security holders, with no new material events or financial disclosures.
Key Players & Entities
- Vaxcyte, Inc. (company) — Registrant
- SutroVax, Inc. (company) — Former company name
- June 12, 2025 (date) — Earliest event reported
- June 17, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders as of June 12, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Vaxcyte, Inc.
On what date was this report filed?
This report was filed on June 17, 2025.
What was Vaxcyte, Inc.'s former name?
Vaxcyte, Inc.'s former name was SutroVax, Inc.
What is the principal executive office address for Vaxcyte, Inc.?
The address of the Principal Executive Offices is 825 Industrial Road, Suite 300, San Carlos, California 94070.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Vaxcyte, Inc. (PCVX).